Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study

Chuan Shi,1–4 Shu Qiao Yao,5 Yi Feng Xu,6 Jian Guo Shi,7 Xiu Feng Xu,8 Cong Pei Zhang,9 Hua Jin,10 Xin Yu1–4 1Clinical Research Center, Peking University Sixth Hospital, 2Clinical Research Center, Peking University Institute of Mental Health, 3Key Laboratory of Mental Health, Min...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shi C, Yao SQ, Xu YF, Shi JG, Xu XF, Zhang CP, Jin H, Yu X
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	paliperidone schizophrenia neurocognition social function Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/ca54b382a066491a80f51f713acc0f21
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ca54b382a066491a80f51f713acc0f21
record_format	dspace
spelling	oai:doaj.org-article:ca54b382a066491a80f51f713acc0f212021-12-02T02:32:25ZImprovement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study1178-2021https://doaj.org/article/ca54b382a066491a80f51f713acc0f212016-08-01T00:00:00Zhttps://www.dovepress.com/improvement-in-social-and-cognitive-functioning-associated-with-palipe-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Chuan Shi,1–4 Shu Qiao Yao,5 Yi Feng Xu,6 Jian Guo Shi,7 Xiu Feng Xu,8 Cong Pei Zhang,9 Hua Jin,10 Xin Yu1–4 1Clinical Research Center, Peking University Sixth Hospital, 2Clinical Research Center, Peking University Institute of Mental Health, 3Key Laboratory of Mental Health, Ministry of Health (Peking University), 4National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 5Clinical Center of Psychology, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, 6Department of Psychiatry, Institute of Mental Health, Shanghai Jiao Tong University, Shanghai, 7Department of Psychiatry, Xi’an Mental Health Center, Xian, Shanxi Province, 8Department of Psychiatry, The First Affiliated Hospital of Kunming Medical School, Kunming, Yunnan Province, 9Department of Psychiatry, The First Haerbin Psychiatric Hospital, Haerbin, Heilongjiang Province, People’s Republic of China; 10Department of Psychiatry, University of California at San Diego, La Jolla, San Diego, CA, USA Purpose: This single-arm, open-label study aimed to explore the effects of extended-release paliperidone on social and cognitive function in patients with schizophrenia.Methods: Paliperidone extended-release (flexible dose ranging from 3 to 12 mg/day orally) was administered for 24 weeks in patients with schizophrenia. Patient function was assessed using the personal and social performance scale, measurement and treatment research to improve cognition in schizophrenia initiative-consensus cognitive battery, positive and negative syndrome scale, and clinical global impression-severity.Results: Ninety patients were included in the full analysis set, while 72 patients were included in the per protocol set. The personal and social performance score was 54.3±14.3 at baseline, and significantly increased to 73.4±12.6 at week 24 (P<0.001). For the measurement and treatment research to improve cognition in schizophrenia initiative-consensus cognitive battery assessment, six of the nine individual subtests, six of the seven cognitive domains, and total cognitive scores improved significantly (P<0.05) between baseline and endpoint. positive and negative syndrome scale total scores and clinical global impression-severity scores decreased gradually (P<0.001) from week 4 to the conclusion of the study.Conclusion: Paliperidone extended-release treatment significantly improves social and neurocognitive function as well as symptoms in Chinese patients with schizophrenia. Keywords: paliperidone, schizophrenia, neurocognition, social functionShi CYao SQXu YFShi JGXu XFZhang CPJin HYu XDove Medical Pressarticlepaliperidoneschizophrenianeurocognitionsocial functionNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 12, Pp 2095-2104 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	paliperidone schizophrenia neurocognition social function Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	paliperidone schizophrenia neurocognition social function Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Shi C Yao SQ Xu YF Shi JG Xu XF Zhang CP Jin H Yu X Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
description	Chuan Shi,1–4 Shu Qiao Yao,5 Yi Feng Xu,6 Jian Guo Shi,7 Xiu Feng Xu,8 Cong Pei Zhang,9 Hua Jin,10 Xin Yu1–4 1Clinical Research Center, Peking University Sixth Hospital, 2Clinical Research Center, Peking University Institute of Mental Health, 3Key Laboratory of Mental Health, Ministry of Health (Peking University), 4National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, 5Clinical Center of Psychology, The Second Xiangya Hospital, Central South University, Changsha, Hunan Province, 6Department of Psychiatry, Institute of Mental Health, Shanghai Jiao Tong University, Shanghai, 7Department of Psychiatry, Xi’an Mental Health Center, Xian, Shanxi Province, 8Department of Psychiatry, The First Affiliated Hospital of Kunming Medical School, Kunming, Yunnan Province, 9Department of Psychiatry, The First Haerbin Psychiatric Hospital, Haerbin, Heilongjiang Province, People’s Republic of China; 10Department of Psychiatry, University of California at San Diego, La Jolla, San Diego, CA, USA Purpose: This single-arm, open-label study aimed to explore the effects of extended-release paliperidone on social and cognitive function in patients with schizophrenia.Methods: Paliperidone extended-release (flexible dose ranging from 3 to 12 mg/day orally) was administered for 24 weeks in patients with schizophrenia. Patient function was assessed using the personal and social performance scale, measurement and treatment research to improve cognition in schizophrenia initiative-consensus cognitive battery, positive and negative syndrome scale, and clinical global impression-severity.Results: Ninety patients were included in the full analysis set, while 72 patients were included in the per protocol set. The personal and social performance score was 54.3±14.3 at baseline, and significantly increased to 73.4±12.6 at week 24 (P<0.001). For the measurement and treatment research to improve cognition in schizophrenia initiative-consensus cognitive battery assessment, six of the nine individual subtests, six of the seven cognitive domains, and total cognitive scores improved significantly (P<0.05) between baseline and endpoint. positive and negative syndrome scale total scores and clinical global impression-severity scores decreased gradually (P<0.001) from week 4 to the conclusion of the study.Conclusion: Paliperidone extended-release treatment significantly improves social and neurocognitive function as well as symptoms in Chinese patients with schizophrenia. Keywords: paliperidone, schizophrenia, neurocognition, social function
format	article
author	Shi C Yao SQ Xu YF Shi JG Xu XF Zhang CP Jin H Yu X
author_facet	Shi C Yao SQ Xu YF Shi JG Xu XF Zhang CP Jin H Yu X
author_sort	Shi C
title	Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
title_short	Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
title_full	Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
title_fullStr	Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
title_full_unstemmed	Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
title_sort	improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/ca54b382a066491a80f51f713acc0f21
work_keys_str_mv	AT shic improvementinsocialandcognitivefunctioningassociatedwithpaliperidoneextendedreleasetreatmentinpatientswithschizophreniaa24weeksinglearmopenlabelstudy AT yaosq improvementinsocialandcognitivefunctioningassociatedwithpaliperidoneextendedreleasetreatmentinpatientswithschizophreniaa24weeksinglearmopenlabelstudy AT xuyf improvementinsocialandcognitivefunctioningassociatedwithpaliperidoneextendedreleasetreatmentinpatientswithschizophreniaa24weeksinglearmopenlabelstudy AT shijg improvementinsocialandcognitivefunctioningassociatedwithpaliperidoneextendedreleasetreatmentinpatientswithschizophreniaa24weeksinglearmopenlabelstudy AT xuxf improvementinsocialandcognitivefunctioningassociatedwithpaliperidoneextendedreleasetreatmentinpatientswithschizophreniaa24weeksinglearmopenlabelstudy AT zhangcp improvementinsocialandcognitivefunctioningassociatedwithpaliperidoneextendedreleasetreatmentinpatientswithschizophreniaa24weeksinglearmopenlabelstudy AT jinh improvementinsocialandcognitivefunctioningassociatedwithpaliperidoneextendedreleasetreatmentinpatientswithschizophreniaa24weeksinglearmopenlabelstudy AT yux improvementinsocialandcognitivefunctioningassociatedwithpaliperidoneextendedreleasetreatmentinpatientswithschizophreniaa24weeksinglearmopenlabelstudy
_version_	1718402437516099584

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study

Ejemplares similares